While Biogen Inc. executives teased the possibility of an early regulatory filing for the Alzheimer's candidate BAN2401 the day before additional data were presented, the Phase II data released July 25 at the Alzheimer’s Association International Conference (AAIC) raised enough concerns that an accelerated filing appears risky.
Detailed results from the 856-patient, Phase II Study 201 at 18 months were presented on July 25 at the AAIC meeting in Chicago
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?